Retatrutide Price per Month: The Short Answer

The closest concrete figures are what approved weight-loss medicines cost today. At the manufacturers' own self-pay prices, tirzepatide (Zepbound) costs $299 to $449 a month, orforglipron (Foundayo) $149 to $299, and semaglutide (Wegovy) $149 to $299 as a daily tablet and $199 to $399 as a weekly injection, depending on the dose and conditions. For people whose commercial insurance covers these drugs, the manufacturers' savings programs advertise costs as low as $25 a month for those who qualify. List prices, the starting point for insurance, are higher: semaglutide's injection is listed at $1,349.02 per package, and Novo Nordisk has said its list price will be $675 per month from January 1, 2027.

Retatrutide itself has no price per month yet, with or without insurance. It is an investigational medicine that no regulator has approved, and its developer has not announced what it will charge. A price would normally be set only after approval, and on the FDA's review goals an approval decision would come in the second half of 2027 at the earliest. The prices above are not a guide to what retatrutide will cost, but they show the range it would enter.

What Approved Weight-Loss Medicines Cost Now

‍
Both companies attach conditions to their self-pay prices. Lilly's prices for tirzepatide 7.5 mg and above and orforglipron 14.5 mg and 17.2 mg apply when a refill is made within 45 days, and the 2.5 mg and 5.5 mg orforglipron doses are temporarily reduced through December 31, 2026. Novo Nordisk's $199 price for the 0.25 mg and 0.5 mg semaglutide injections is for new patients only, for two monthly fills, through December 31, 2026, and the company says its pricing will be updated after that date.

The $25 figures are for people with commercial insurance that covers the drug, and both companies set eligibility rules and limits; Novo Nordisk, for example, caps the savings at $100 a month. People with government insurance, such as Medicare, are excluded from these insured offers. Otherwise, what insured patients pay depends on the plan, and coverage of these drugs for weight management varies from plan to plan.

How retatrutide's trial results compare with these drugs is covered in retatrutide vs tirzepatide vs semaglutide and retatrutide vs orforglipron.

Where the $1,000 to $1,500 Figures Come From

Searches for retatrutide's price often turn up monthly figures of about $1,000 to $1,500. These are not prices. They are websites' own projections, not attributed to the drug's developer or to any named analyst, and they sit in the range of current list prices for approved drugs, such as semaglutide's $1,349.02. As of October 2026 we have not found a published estimate from the drug's developer, a named analyst or a major news outlet.

The other numbers in search results are prices for vials sold online under the retatrutide name. Those are not sold or supplied by Lilly. In August 2026, the company said: "No medicine containing retatrutide has yet been approved for human use by any regulatory agency in the world. It cannot be sold to consumers." Its retatrutide page warns that illicit retatrutide products "may contain unknown ingredients, harmful contaminants and impurities," and the trial results described elsewhere on this site do not apply to them.

The company's retatrutide page (updated September 2026) says it is legally available only through its clinical trials. In August 2026, according to STAT, the company also said it would make it available to a limited number of patients who meet specific medical criteria and cannot enroll in a trial; that is a medical access route through a doctor, not a retail sale.

What Will Decide Retatrutide's Price?

The company has said only how it intends to approach the question. Its retatrutide page says: "Upon completion of clinical trials and the regulatory review process, we plan to ensure retatrutide is priced to reflect the overall value to the healthcare system." Its announcements of the Phase 3 results, including the most recent, on September 29, 2026, do not mention a price or insurance coverage.

Beyond that, the price of an approved drug depends on the label it receives, the competition at the time, and negotiations with insurers and government programs. The competition is already moving: semaglutide's list price is scheduled to fall by about half from January 2027, and self-pay prices for tirzepatide, orforglipron and semaglutide tablets are well below semaglutide's current list price. None of these factors can be applied to retatrutide until it has a label.

When Could Retatrutide Have a Price?

Not before an approval decision. The company plans to submit its application to the FDA in the first quarter of 2027. Under the FDA's review goals for a new molecule, a standard review aims for a decision about 12 months after submission, and a priority review about 8 months after. Those are targets, not guarantees, and the FDA can also ask for more data.

So any retatrutide price is, at the earliest, a question for the second half of 2027.

Will Insurance Cover Retatrutide?

Nobody can say yet. Insurers decide coverage for a drug after it is approved, based on its label, its price and the alternatives. No plan covers retatrutide today because there is nothing to cover.

Medicare offers a useful example of how timing matters. Under a temporary program called the Medicare GLP-1 Bridge, which runs from July 1, 2026, to December 31, 2027, eligible people with Medicare Part D drug coverage pay $50 a month for three named drugs: orforglipron tablets, semaglutide injections or tablets, and tirzepatide multi-dose pens. Eligibility depends on BMI and certain health conditions. Retatrutide is not on that list, and the program is scheduled to end around the time an approval decision on retatrutide would be expected.

Why This Page Has No Price Estimate of Its Own

Earlier versions of articles like this one, including ours, projected a monthly price, insurance scenarios and copay-card savings for retatrutide. We have removed them. There is no price, no copay program and no coverage decision to report, and a projected figure presented next to real prices for approved drugs is easy to mistake for a fact.

We will update this page when a price is announced.

Retatrutide Price in Summary

Approved GLP-1 weight-loss medicines cost $149 to $449 a month at the manufacturers' self-pay prices, depending on the drug, dose and conditions, and as little as $25 a month for eligible patients whose commercial insurance covers them; semaglutide's injection list price is $1,349.02 per package, scheduled to become $675 per month in January 2027. Retatrutide has no price per month because it is not approved, and its developer has said only that it plans to price it "to reflect the overall value to the healthcare system." A price is unlikely before the second half of 2027. Figures of $1,000 to $1,500 a month seen online are not prices, and products sold online under the name are not sold or supplied by Lilly.

Sources

• Eli Lilly. What to know about retatrutide. Last updated September 2026.
• Eli Lilly. Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market. August 12, 2026.
• Eli Lilly. Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes. September 29, 2026.
• Eli Lilly. Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C. July 23, 2026.
• STAT. Eli Lilly to allow more patients to apply for special access to unapproved obesity drug. August 3, 2026.
• U.S. Food and Drug Administration. PDUFA Reauthorization Performance Goals and Procedures, Fiscal Years 2023 Through 2027.
• Eli Lilly. LillyDirect self-pay pricing pages for tirzepatide and orforglipron. Checked October 19, 2026.
• Novo Nordisk. NovoCare savings offer and self-pay pricing for semaglutide (Wegovy) injection and tablets. Checked October 19, 2026.
• Novo Nordisk. Explaining list price (NovoCare, Wegovy).
• Novo Nordisk. Novo Nordisk announces significant reduction in US list price for Wegovy, Ozempic, and Rybelsus (semaglutide medicines). February 24, 2026.
• Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge, and Medicare GLP-1 Bridge: GLP-1 Drugs for $50 a Month (fact sheet).

Medical Disclaimer: This article is for informational purposes only and is not medical, financial or insurance advice. Retatrutide is investigational and is not approved by the FDA for any use. It is not available by prescription, and products sold online under its name are not sold or supplied by Lilly. Prices for approved medicines are the manufacturers' published prices on the dates shown and may change. Nothing here is a recommendation to use, seek out or avoid any medication.